{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this notice to Cytovia Therapeutics (\"Cytovia\") located in New York, NY.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2020/07/30/2020-16486.html","cfr_references":[],"citation":"85 FR 45912","comment_url":null,"comments_close_on":"2020-08-14","correction_of":null,"corrections":[],"dates":"Only written comments and/or complete applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before August 14, 2020 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2020-16486","effective_on":null,"end_page":45912,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2020/07/30/2020-16486.xml","html_url":"https://www.federalregister.gov/documents/2020/07/30/2020-16486/prospective-grant-of-an-exclusive-patent-license-allogeneic-therapy-using-chimeric-antigen-receptors","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2020-16486?publication_date=2020-07-30","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2020-07-30/2020-16486/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":359,"last_updated":"2026-06-23 20:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2020-07-30/pdf/2020-16486.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2020-16486.pdf?1596026722","publication_date":"2020-07-30","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2020/07/30/2020-16486.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T03:50:27Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":45912,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Allogeneic Therapy Using Chimeric Antigen Receptors Targeting GPC3","toc_doc":"Allogeneic Therapy using Chimeric Antigen Receptors Targeting Glypican-3","toc_subject":"Prospective Grant of an Exclusive Patent License:\n","topics":[],"type":"Notice","volume":85}